Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta, Is Entitled To Receive 85% Economic Interest In Closed Triple Royalties Paid By GSK